Degarelix
A gonadotropin-releasing hormone (GnRH) antagonist that rapidly lowers testosterone levels in men with prostate cancer. Unlike GnRH agonists, it works immediately without an initial testosterone surge.
Berat Molekul
1632,3000 g/mol
LogP
3,50
TPSA
513,00 Ų
Lipinski RO5
Gagal
Area Terapeutik
Mekanisme Kerja
Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
InChI
InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
Molecular Formula
C82H103ClN18O16
HBD / HBA
17 / 18
Ikatan yang Dapat Dirotasi
41
Atom Berat
117
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A gonadotropin-releasing hormone (GnRH) antagonist that rapidly lowers testosterone levels in men with prostate cancer. Unlike GnRH agonists, it works immediately without an initial testosterone surge.
Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.
Yes, Degarelix is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL415606. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16136245. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="degarelix"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/degarelix/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/degarelix/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/degarelix/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="degarelix"></drugfyi-drug>